SON-1010 is under clinical development by Sonnet BioTherapeutics and currently in Phase I for Mesenchymal Tumor. According to GlobalData, Phase I drugs for Mesenchymal Tumor have an 82% phase ...

(REUTERS) At 9.30am, the 30-share BSE benchmark Sensex was down by 1,010 points to 79,171. The NSE Nifty dropped 302 points to 23,895. All the 30 blue-chip stocks were trading lower. Infosys ...

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months ...